<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5330">
  <stage>Registered</stage>
  <submitdate>16/11/2015</submitdate>
  <approvaldate>16/11/2015</approvaldate>
  <nctid>NCT02656537</nctid>
  <trial_identification>
    <studytitle>EnSite HD Grid Catheter AF/AT Mapping Study</studytitle>
    <scientifictitle>EnSite HD Grid Catheter Mapping System for Advanced High Density Three-Dimensional Mapping in Non-Paroxysmal Atrial Fibrillation and Atrial Tachycardia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CRD772</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Non-paroxysmal Atrial Fibrillation</healthcondition>
    <healthcondition>Left Atrial Tachycardia</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - EnSite HD Grid Catheter mapping system

Experimental: EnSite HD Grid Catheter AF/AT Mapping - 


Treatment: devices: EnSite HD Grid Catheter mapping system


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of subjects with adverse events associated with the use of the EnSite HD (High-Density)Grid Catheter mapping system. - To evaluate the safety of the novel EnSite HD Grid Catheter mapping system by collecting intra- and post-Procedure (within 48 hours from Procedure) adverse events.</outcome>
      <timepoint>Within 48 hours from Procedure</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of subjects with the electrophysiological characteristics of non-paroxysmal AF and left AT pre-catheter ablation studied using the EnSite HD Grid Catheter mapping system. - To identify and study the electrophysiological characteristics of non-paroxysmal AF and left AT pre-catheter ablation using a novel EnSite HD Grid Catheter mapping system.</outcome>
      <timepoint>During Procedure</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Catheter performance during the mapping portion of the procedure - To assess the HD Grid Catheter mapping system for acceptable geometry creation, map repeatability and electrogram signal quality.</outcome>
      <timepoint>During Procedure</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Presence of non-paroxysmal atrial fibrillation (AF) or left atrial tachycardia (AT)
             referred for catheter ablation

          2. Age of 18 years of age or older at time of Enrollment

          3. On continuous anticoagulation (INR 2-3) for &gt;4 weeks prior to the ablation

          4. Able and willing to provide written informed consent to participate in this clinical
             investigation</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Secondary atrial fibrillation (AF)

          2. Presence of a prosthetic valve(s) or hemodynamically significant valvular heart
             disease as determined by Study Investigator

          3. Active systemic infection (e.g. sepsis)

          4. Presence of left atrial thrombus (i.e., positive TEE) or myxoma, or interatrial baffle
             or patch via the transseptal approach

          5. Contraindication to systemic anticoagulation (i.e., heparin, warfarin, or a direct
             thrombin inhibitor)

          6. History of cerebrovascular accidents (Stroke, TIA)

          7. Previous myocardial infarction, unstable angina pectoris or coronary artery by-pass
             &lt;180 days at Enrollment or cardiovascular intervention expected in the 180 days
             post-Enrollment

          8. Left atrial size &gt;55mm

          9. NYHA (New York Heart Association Classification) functional class III or IV heart
             failure

         10. Left ventricular ejection fraction &lt;35%

         11. Uncontrolled Hyperthyroidism

         12. Pregnant or of childbearing potential and not using adequate contraceptive methods or
             nursing

         13. Participating in another clinical investigation that may confound the results of this
             clinical investigation

         14. Life expectancy less than 12 months, as determined by Study Investigator

         15. Severe clinical condition (e.g. active carcinoma) that, in the opinion of the Study
             Investigator, excludes the participation in the study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/07/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Ashford Hospital - Ashford</hospital>
    <hospital>Royal Melbourne Hospital - Parkville</hospital>
    <postcode> - Adelaide</postcode>
    <postcode>5035 - Ashford</postcode>
    <postcode>3050 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pessac</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>St. Jude Medical</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>In this clinical investigation, the safety, feasibility and performance of the novel EnSite
      HD Grid Catheter mapping system for advanced high-density three-dimensional mapping will be
      studied in patients undergoing catheter ablation procedures for the treatment of
      non-paroxysmal atrial fibrillation (AF) or left atrial tachycardia (AT).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02656537</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Carlo Pappone, MD, PhD</name>
      <address>San Donato Hospital, Italy</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>